These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11427434)

  • 1. Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.
    Sarmati L; d'Ettorre G; Nicastri E; Ercoli L; Uccella I; Massetti P; Parisi SG; Vullo V; Andreoni M
    Clin Diagn Lab Immunol; 2001 Jul; 8(4):822-4. PubMed ID: 11427434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.
    Sarmati L; Nicastri E; el-Sawaf G; Ventura L; Salanitro A; Ercoli L; Vella S; Andreoni M
    J Med Virol; 1997 Dec; 53(4):313-8. PubMed ID: 9407377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 IgA specific serum antibodies and disease progression during HIV-1 infection.
    Margalith M; Levy E; Rinaldo CR; Detels R; Phair J; Kaslow R; Saah AJ; Sarov B
    J Hum Virol; 2001; 4(5):269-77. PubMed ID: 11907384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
    Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
    Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.
    Pantaleo G; Menzo S; Vaccarezza M; Graziosi C; Cohen OJ; Demarest JF; Montefiori D; Orenstein JM; Fox C; Schrager LK
    N Engl J Med; 1995 Jan; 332(4):209-16. PubMed ID: 7808486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
    Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
    J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.